Neuro-Oncology Advances,
Journal Year:
2024,
Volume and Issue:
6(1)
Published: Jan. 1, 2024
Abstract
The
phase-3
INDIGO
trial
demonstrated
that
the
isocitrate
dehydrogenase
(IDH)
inhibitor
vorasidenib
significantly
prolonged
progression-free
survival
and
delayed
intervention
in
patients
with
CNS
WHO
grade
2
gliomas.
However,
conventional
MRI
showed
limited
response,
only
11%
of
having
objective
responses.
Studies
suggest
serial
PET
imaging
radiolabeled
amino
acids,
such
as
O
-(2-[18
F]-fluoroethyl)-L-tyrosine
(FET)
PET,
may
provide
earlier
more
informative
assessments
treatment
response
than
MRI.
In
an
initial
experience
FET
3
out
5
metabolic
to
vorasidenib.
This
highlights
PET’s
potential
guide
decision-making,
though
further
trials
are
needed
confirm
outcome
benefits.
Korean Journal of Radiology,
Journal Year:
2024,
Volume and Issue:
26
Published: Jan. 1, 2024
Owing
to
recent
advancements
in
various
postoperative
treatment
modalities,
such
as
radiation,
chemotherapy,
antiangiogenic
treatment,
and
immunotherapy,
the
radiological
clinical
assessment
of
patients
with
isocitrate
dehydrogenase-wildtype
glioblastoma
using
post-treatment
imaging
has
become
increasingly
challenging.
This
review
highlights
challenges
differentiating
treatment-related
changes
pseudoprogression,
radiation
necrosis,
pseudoresponse
from
true
tumor
progression
aims
serve
a
guideline
for
efficient
communication
clinicians
optimal
management
imaging.
Life,
Journal Year:
2024,
Volume and Issue:
14(10), P. 1312 - 1312
Published: Oct. 16, 2024
Using
microRNAs
(miRNAs)
as
potential
circulating
biomarkers
in
diagnosing
and
treating
glioblastoma
(GBM)
has
garnered
a
lot
of
scientific
clinical
impetus
the
past
decade.
As
an
aggressive
primary
brain
tumor,
GBM
poses
challenges
early
detection
effective
treatment
with
significant
current
diagnostic
constraints
limited
therapeutic
strategies.
MiRNA
dysregulation
is
present
GBM.
The
intricate
involvement
miRNAs
altering
cell
proliferation,
invasion,
immune
escape
makes
them
prospective
candidates
for
identifying
monitoring
diagnosis
response
to
treatment.
These
could
play
dual
role,
acting
both
markers
targets
therapy.
By
modulating
activity
various
oncogenic
tumor-suppressive
proteins,
create
opportunities
precision
medicine
targeted
therapies
This
review
centers
on
critical
role
function
miRNA
It
highlights
their
significance
providing
insights
into
disease
progression,
aiding
diagnosis,
use
novel
interventions.
Ultimately,
study
would
contribute
improving
patient
outcomes
challenging
landscape
management.
Neuro-Oncology Advances,
Journal Year:
2024,
Volume and Issue:
6(1)
Published: Jan. 1, 2024
Abstract
The
phase-3
INDIGO
trial
demonstrated
that
the
isocitrate
dehydrogenase
(IDH)
inhibitor
vorasidenib
significantly
prolonged
progression-free
survival
and
delayed
intervention
in
patients
with
CNS
WHO
grade
2
gliomas.
However,
conventional
MRI
showed
limited
response,
only
11%
of
having
objective
responses.
Studies
suggest
serial
PET
imaging
radiolabeled
amino
acids,
such
as
O
-(2-[18
F]-fluoroethyl)-L-tyrosine
(FET)
PET,
may
provide
earlier
more
informative
assessments
treatment
response
than
MRI.
In
an
initial
experience
FET
3
out
5
metabolic
to
vorasidenib.
This
highlights
PET’s
potential
guide
decision-making,
though
further
trials
are
needed
confirm
outcome
benefits.
